Clinical trial NCT04060758: Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma
Official title: An Open Label, Comparative, Sequential-dose, Multi-centre Study Involving Intracameral Administration of a PA5108 Latanoprost FA SR Ocular Implant Into the Eye of Patients With Mild-moderate Glaucoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Open Angle Glaucoma
Lead sponsor: PolyActiva Pty Ltd
Sponsor class: INDUSTRY
First posted: 2019-08-19
Enrollment: 37
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a multi-centre, open label, interventional, comparative, phase I study to identify a safe and efficacious dose (within the range of 14.7mcg to 35.5 mcg) of PA5108 (PolyActiva product code) Latanoprost free acid (FA) sustained release (SR) Ocular Implant in adults who have Primary Open Angle Glaucoma.

Detailed description: This is a multi-centre, open label, interventional, comparative, phase Ib dose ranging study to identify a safe and efficacious dose (within the range of 14.7 to 35.5 microgram) of PA5108 Latanoprost FA SR Ocular Implant in adults who have Primary Open Angle Glaucoma (POAG).

The proposed study is a single ascending dose design to determine the minimum effective dose that provides the target of \>20% IOP lowering effect at 12 weeks with minimal adverse events.

Up to three single-dose cohorts will be assessed from the following implant strengths:

* 35.5 microgram
* 26.6 microgram
* 14.7 microgram

In addition, a repeat-dose cohort will be assessed from the following implant strength:

o 14.7 microgram

A first cohort of participants will be recruited and dosed with the 14.7 mcg PA5108 Latanoprost FA SR Ocular Implant. A second cohort of participants will be recruited after SMC review of 6-week data of the first cohort and dosed with the 26.6 mcg PA5108 Latanoprost FA SR Ocular Implant. A third cohort of participants will be recruited after SMC review of 6-week data of the second cohort and repeat-dosed with 14.7 mcg PA5108 Latanoprost FA SR Ocular Implant. A fourth cohort of participants will be recruited and dosed with the 35.5 mcg PA5108 Latanoprost FA SR Ocular Implant

Prior to study registration, participants will have been medicated with intraocular pressure (IOP) lowering drop therapy, including a prostaglandin analogue, to manage their POAG. The IOP lowering drops will be stopped in the intent to treat eye within 29 to 43 days prior to the date of implant administration. Participants will be required to have an unmedicated (post wash-out) 8:00am IOP ≥ 24 mmHg and ≤ 36mmHg in the intent to treat eye at either of two screening visits 2-weeks apart. Additionally, the IOP at 12:00 noon and 4:00 pm must be ≥ 20mmHg and ≤ 36mmHg on the same screening visit where the 8:00am IOP was ≥ 24 mmHg and ≤ 36mmHg.

The PA5108 Latanoprost FA SR Ocular Implant will be administered to one eye (unilateral) of each participant.

IOP will be monitored and if after implant administration is found to rise ≥30% over baseline in the study eye, IOP lowering eye drops will be restarted.

The study will recruit up to 10 participants per cohort/dose level. After screening, eligible participants enrolled in the single-dose cohorts will be administered a single PA5108 Latanoprost FA SR Ocular Implant by clear corneal injection to the anterior chamber of the eye, by means of a custom-built injector fitted with a 27G pre-loaded needle at Day 0. Whereas eligible participants enrolled in the repeat-dose cohort will be administered a single PA5108 Latanoprost FA SR Ocular Implant by clear corneal injection to the anterior chamber of the eye, by means of a custom-built injector fitted with a 27G pre-loaded needle at Day 0, and again at Week 21.

The study will end at the later of Visit 12 (48-weeks) for the last participant in the repeat dose cohort, or when the last of the study implants are no longer visible in the study eye and the IOP in the same eye has returned to a normal clinical care range, or 12-weeks has passed since the implant was no longer visible regardless of IOP.

Participants in the single dose cohorts will attend the study site for follow up on Day 1 post implant administration, and then Week 6, 12, (optionally 15), 18, (optionally 21), 26, 32 and if required subsequent 6-week intervals until the implant has completely biodegraded and the IOP of the same eye has returned to normal clinical care range or 12-weeks has passed since the implant was no longer visible. Implant biodegradation will be confirmed by biomicroscopy and gonioscopy examination at Week 6, 12, optionally 15, 18, optionally 21, 26 \& 32, and if necessary, every 6-weeks thereafter.

Participants in the repeat dose cohort will attend the study site for follow up on Day 1 post implant administration, and then Week 6, 12,18, Week 21 (when they will be administered the second dose), Day 1 post repeat dose, Week 27, 33, 42, 48 and if required subsequent 6-week intervals until the implant has completely biodegraded and the IOP of the same eye has returned to normal clinical care range or 12-weeks has passed since the implant was no longer visible. Implant biodegradation will be confirmed by biomicroscopy and gonioscopy examination at Week 6,12,18, 21,27, 33,42 \& 48, and if necessary, every 6-weeks thereafter.

Eligibility criteria: Inclusion Criteria:

Participants who:

* Diagnosis of primary open angle glaucoma.
* Unmedicated 8:00am IOP ≥ 24 mmHg and ≤ 36mmHg in the intent to treat eye. Additionally, the IOP at 12:00 and 16:00 hrs must be ≥ 20mmHg and ≤ 36mmHg.
* Corrected visual acuity in each eye greater than or equal to +0.3logMAR.
* Minimum central endothelial cell density of greater than or equal to 1600 cells per mm2
* Currently managing their POAG with IOP lowering drop therapy.

Exclusion Criteria:

Participants who:

* Have pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles.
* Have a history of or current ocular inflammation.
* Have aphakic eyes or only one eye.
* Recent surgery in the study eye surgery (including laser).
* Clinically significant ocular disease in either eye (e.g., corneal oedema, uveitis, severe keratoconjunctivitis sicca or infection) which might interfere with the study.
* Known sensitivity to any component of the product (e.g. latanoprost or polytriazole sensitivity), or to topical therapy used during course of study (e.g. povidone iodine, or anaesthetics).
* Ocular medication in either eye of any kind within 30 days of screening.
* Central corneal thickness in either eye that is less than 470 µm or greater than 630 µm at screening (or a difference between the eyes \>70 µm).
* Any abnormality in either eye preventing reliable applanation tonometry, including aphakic eyes or significant corneal guttatae.
* Any other clinically significant disease (as determined by physician) which might interfere with the study.

Primary outcomes:
measure: Effective dose
timeFrame: Intraocular Pressure (IOP) change measured at; baseline, week 12 and week 26.
measure: Safety and Tolerability-incidence of treatment emergent Adverse Events
timeFrame: Incidence of Treatment-Emergent Adverse Events throughout the study (up to 1 year).
Secondary outcomes:
measure: Ease of Use
timeFrame: At visit 2-Day 0, after use of device to insert the implant into the eye.
Other outcomes:
Locations:
city: Castle Hill
country: Australia
facility: PersonalEYES
state: New South Wales
city: Millswood
country: Australia
facility: Goodwood Eye Centre
state: South Australia
city: Bendigo
country: Australia
facility: Bendigo Eye Clinic
state: Victoria
city: East Melbourne
country: Australia
facility: Centre for Eye Research Australia
state: Victoria
city: Essendon
country: Australia
facility: Essendon Eye Clinic
state: Victoria
city: Fitzroy
country: Australia
facility: Melbourne Eye Specialists
state: Victoria
city: Springvale
country: Australia
facility: Eyes First
state: Victoria
city: Vermont South
country: Australia
facility: Eye Surgery Associates
state: Victoria
city: Te Aro
country: New Zealand
facility: Capital Eye Specialists
Study officials:
affiliation: Melbourne Eye Specialists
name: Michael Coote
role: PRINCIPAL_INVESTIGATOR
References: